CN105541859A - 二氢呋喃并色满酮衍生物及其制备方法与医药用途 - Google Patents
二氢呋喃并色满酮衍生物及其制备方法与医药用途 Download PDFInfo
- Publication number
- CN105541859A CN105541859A CN201610098585.4A CN201610098585A CN105541859A CN 105541859 A CN105541859 A CN 105541859A CN 201610098585 A CN201610098585 A CN 201610098585A CN 105541859 A CN105541859 A CN 105541859A
- Authority
- CN
- China
- Prior art keywords
- chroman
- dihydro
- furo
- dimethyl
- benzylidene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- -1 methoxyl groups Chemical group 0.000 claims abstract description 37
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
- 239000001257 hydrogen Substances 0.000 claims abstract description 16
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 10
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims abstract description 7
- 239000002911 sialidase inhibitor Substances 0.000 claims abstract description 7
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims abstract description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 4
- 229910052805 deuterium Inorganic materials 0.000 claims abstract description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- 102000005348 Neuraminidase Human genes 0.000 description 12
- 108010006232 Neuraminidase Proteins 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000001953 recrystallisation Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 4
- 229960003752 oseltamivir Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000124209 Crocus sativus Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- WJGPNUBJBMCRQH-UHFFFAOYSA-N 2,2-dimethyl-2,3-dihydro-1-benzofuran-7-ol Chemical compound C1=CC(O)=C2OC(C)(C)CC2=C1 WJGPNUBJBMCRQH-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- GQXWKFSCBLCMJX-UHFFFAOYSA-N 2-chloro-1-pyrazol-1-ylethanone Chemical class ClCC(=O)N1C=CC=N1 GQXWKFSCBLCMJX-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical class C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KFIQGDOAAUVVPC-VIFPVBQESA-N C=C(COC1=C2C=CC=C3[C@H]12)C3=O Chemical compound C=C(COC1=C2C=CC=C3[C@H]12)C3=O KFIQGDOAAUVVPC-VIFPVBQESA-N 0.000 description 1
- 0 C[*+]c1cccc(C=CC=O)c1 Chemical compound C[*+]c1cccc(C=CC=O)c1 0.000 description 1
- 235000007627 Caesalpinia Nutrition 0.000 description 1
- 241000522234 Caesalpinia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical group [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005605 benzo group Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000008375 benzopyrones Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
本发明公开了结构式Ⅰ所示的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物及其药学上可接受的盐,其制备方法和药物组合物以及其在制备流感病毒神经氨酸酶抑制剂中的应用。其中R选自:氢、氘、C1~C2烷基、C3~C5直链烷基或C3~C5支链烷基;X1、X5选自:氢、C1~C2烷基、C3~C4直链或支链烷基、羟基、甲氧基、乙氧基;X2、X4选自:氢、C1~C2烷基、C3~C4直链或支链烷基、硝基、羟基、甲氧基、乙氧基或氨基;X3选自:氢、C1~C2烷基、C3~C4直链或支链烷基,羟基、甲氧基、乙氧基、二甲氨基或羧基。
Description
技术领域
本发明涉及一类新化合物的制备与应用;具体是7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物的制备与作为流感病毒神经氨酸酶抑制剂的应用。
背景技术
苯并吡喃酮类化合物在自然界分布广泛,其基本结构或类似物在许多生物的次生代谢产物中都能找到,说明这种结构对于有机体的生命活动具有至关重要的作用。近年来,许多课题组都经分离或合成手段得到了苯并吡喃酮的衍生物,同时也针对该类化合物进行了广泛的生物活性测试。PalPerjési等[Eur.J.Med.Chem.,2008,43:839-845]设计合成了12种3-苯亚甲基-4-色满酮类衍生物,其中化合物A1对人肿瘤细胞株Molt4/C8和CEM的平均IC50值分别为5.22μM和4.81μM,显示其具有较强的抗癌活性,且对人体正常细胞具有较低的毒性,小鼠体内测试表明该类化合物优先杀死恶性肿瘤细胞,具有良好的体内相容性。
Alipour等[Daru.J.Pharm.Sci.,2014,22:41]以间苯二酚作为原料合成了一系列3-亚苄基取代的6,7-二氧亚甲基-4-色满酮,并测试了其对三种不同乳腺癌细胞MCF-7、T47D和MDA-MB-231的抑制活性。结果表明化合物A2表现出了对三种癌细胞良好的抑制活性(IC50≤9.3μg/mL)。
除抗癌活性外,许多苯并吡喃酮类化合物还被证实具有抗氧化活性,VidavalurSiddaiah等[Bioorg.Med.Chem.Lett.,2007,17:1288-1290]合成了一系列4-色满酮类似物,其中四羟基取代产物A3具有优异的NBT过氧化抑制活性和DPPH自由基清除活性,其IC50值分别为8.5μM和4.5μM,高于阳性对照组维生素C和BHA。
苯并吡喃酮类化合物还具有单胺氧化酶(MOA)抑制活性,NicolettaDesideri等[J.Med.Chem.,2011,54:2155–2164]设计合成了一系列3-苯亚甲基-色满-4-酮类化合物,其中化合物A4和A5对hMAO-B具有优于阳性对照物selegiline的抑制活性。
2013年,Roy等[Eur.J.Med.Chem.,2013,66:499-507]从间苯二酚出发合成设计了一系列4-色满酮类化合物作为外排泵抑制对结核杆菌具有较好的抑制活性,其中化合物A6~A8最低抑菌浓度小于阳性对照物维拉帕米。
LeeWS等[Biol.Pharm.Bull.,2012,35(5):786-790]从一种苏木科Caesalpinia中提取分离得到12种多羟基苯并吡喃酮类化合物。通过化学发光检测法测试了12种化合物的神经氨酸酶(NA)抑制活性,其中化合物A9对流感病毒H1N1、H3N2、H9N2三种亚型神经氨酸酶具有较好的抑制活性,IC50值分别为0.7μM、1.1μM、1.0μM。
Ryu等[Bioorg.Med.Chem.Lett.,2009,19(17):4912-4915]研究发现了一系列苯并(二氢)吡喃酮类化合物,其中化合物A10具有纳摩尔级的抗流感活性(IC50=380nM),而且研究表明它在动力学上属于非竞争性抑制剂,故其作用机制可能与现有的抗流感药物不同,有望开发成对现有药物耐药病毒株强有效的神经氨酸酶抑制剂,因此对化合物A10的结构进行改造可能发现强有效的神经氨酸酶抑制剂。Dao等[Bioorg.Med.Chem.Lett.,2011,21(1):294-298]从甘草中分离出一种α,β不饱和酮化合物A11,它与奥司他韦联用时,可显著增强奥司他韦对H1N1(H274Y)型流感病毒的抑制活性。研究结果间接的表明它抗流感的作用机制与奥司他韦不同,因此它具有对抗耐奥司他韦流感病毒的潜力。
2012年,胡艾希等[CN102399229B,2013-9-4]报道了一类含苯并吡喃和苯并呋喃环N-酰基吡唑鱼藤酚A12及其制备方法与应用,优选N-氯乙酰基吡唑鱼藤酚在反应系统中检测浓度为40ug/ml,其对神经氨酸酶的抑制率为40%。
发明内容
本发明解决的技术问题是提供一类7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物、其制备方法、药物组合物和用途。
为解决本发明的技术问题,本发明提供如下技术方案:
本发明技术方案的第一方面是提供了一类如化学结构式Ⅰ所示的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物及其药学上可接受的盐:
其中R选自:氢、氘、C1~C2烷基、C3~C5直链烷基或C3~C5支链烷基;X1、X5选自:氢、C1~C2烷基、C3~C4直链或支链烷基、羟基、甲氧基、乙氧基;X2、X4选自:氢、C1~C2烷基、C3~C4直链或支链烷基、硝基、羟基、甲氧基、乙氧基或氨基;X3选自:氢、C1~C2烷基、C3~C4直链或支链烷基,羟基、甲氧基、乙氧基、二甲氨基或羧基。
进一步的,优选的化合物选自:
7-(3-羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(4-羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(3,4-二羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(4-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(3,4,5-三甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(4-羟基-3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(3-羟基-4-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(2-羟基-3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(2-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(3-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(4-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(2-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(3-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(4-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(4-羧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、7-(4-二甲氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮。
本发明技术方案的第二方面是提供了第一方面所述结构式I所示的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物的制备方法,其特征在于它的制备反应如下:
其中R选自:氢、氘、C1~C2烷基、C3~C5直链烷基或C3~C5支链烷基;X1、X5选自:氢、C1~C2烷基、C3~C4直链或支链烷基、羟基、甲氧基、乙氧基;X2、X4选自:氢、C1~C2烷基、C3~C4直链或支链烷基、硝基、羟基、甲氧基、乙氧基或氨基;X3选自:氢、C1~C2烷基、C3~C4直链或支链烷基,羟基、甲氧基、乙氧基、二甲氨基或羧基。
本发明技术方案的第三方面是提供含有第一方面所述化合物及其药学上可接受的盐的药物组合物,该药物组合物含有治疗有效量的本发明的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物及其药学上可接受的盐,以及任选的含有药用载体。其中所述的药用载体指药学领域常用的药用载体;该药物组合物可根据本领域公知的方法制备。可通过将本发明化合物及其药学上可接受的盐与一种或多种药学上可接受的固体或液体赋形剂和/或辅剂组合,制成适于人或动物使用的任何剂型。本发明化合物及其药学上可接受的盐在其药物组合物中的含量通常为0.1%~95%重量百分比。
本发明化合物及其药学上可接受的盐或含有它的药物组合物可以单位剂量形式给药,给药途径可为肠道或非肠道,如口服、静脉注射、肌肉注射、皮下注射、鼻腔、口腔粘膜、眼、肺和呼吸道、皮肤、阴道、直肠等。
给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂(包括真溶液和胶体溶液)、乳剂(包括o/w型、w/o型和复乳)、混悬剂、注射剂(包括水针剂、粉针剂和输液)、滴眼剂、滴鼻剂、洗剂和搽剂等;固体剂型可以是片剂(包括普通片、肠溶片、含片、分散片、咀嚼片、泡腾片、口腔崩解片)、胶囊剂(包括硬胶囊、软胶囊、肠溶胶囊)、颗粒剂、散剂、微丸、滴丸、栓剂、膜剂、贴片、气(粉)雾剂、喷雾剂等;半固体剂型可以是软膏剂、凝胶剂、糊剂等。
本发明化合物及其药学上可接受的盐可以制成普通制剂、也制成是缓释制剂、控释制剂、靶向制剂及各种微粒给药系统。
为了将本发明化合物及其药学上可接受的盐制成片剂,可以广泛使用本领域公知的各种赋形剂,包括稀释剂、黏合剂、润湿剂、崩解剂、润滑剂、助流剂。稀释剂可以是淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素、硫酸钙、磷酸氢钙、碳酸钙等;湿润剂可以是水、乙醇、异丙醇等;粘合剂可以是淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、微晶纤维素、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯吡咯烷酮、聚乙二醇等;崩解剂可以是干淀粉、微晶纤维素、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、羧甲基淀粉钠、碳酸氢钠与枸橼酸、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基磺酸钠等;润滑剂和助流剂可以是滑石粉、二氧化硅、硬脂酸盐、酒石酸、液体石蜡、聚乙二醇等。
还可以将片剂进一步制成包衣片,例如糖包衣片、薄膜包衣片、肠溶包衣片,或双层片和多层片。
为了将给药单元制成胶囊剂,可以将有效成分本发明化合物及其药学上可接受的盐与稀释剂、助流剂混合,将混合物直接置于硬胶囊或软胶囊中。也可将有效成分本发明化合物及其药学上可接受的盐先与稀释剂、黏合剂、崩解剂制成颗粒或微丸,再置于硬胶囊或软胶囊中。用于制备本发明化合物及其药学上可接受的盐片剂的各稀释剂、黏合剂、润湿剂、崩解剂、助流剂品种也可用于制备本发明化合物及其药学上可接受的盐的胶囊剂。
为将本发明化合物及其药学上可接受的盐制成注射剂,可以用水、乙醇、异丙醇、丙二醇或它们的混合物作溶剂并加入适量本领域常用的增溶剂、助溶剂、pH调剂剂、渗透压调节剂。增溶剂或助溶剂可以是泊洛沙姆、卵磷脂、羟丙基-β-环糊精等;pH调剂剂可以是磷酸盐、醋酸盐、盐酸、氢氧化钠等;渗透压调节剂可以是氯化钠、甘露醇、葡萄糖、磷酸盐、醋酸盐等。如制备冻干粉针剂,还可加入甘露醇、葡萄糖等作为支撑剂。
此外,如需要,也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂或其它添加剂。
为达到用药目的,增强治疗效果,本发明的药物或药物组合物可用任何公知的给药方法给药。
本发明技术方案的第四方面是提供本发明第一方面所述7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物及其药学上可接受的盐以及第三方面所述药物组合物在制备流感病毒神经氨酸酶抑制剂方面的应用。
有益技术效果:
本发明的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物是一类新结构类型的具有流感病毒神经氨酸酶抑制活性的化合物。
具体实施方式
以下实施例旨在说明本发明而不是对本发明的进一步限定。
实施例1
2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
(1)3-((2,2-二甲基-2,3-二氢苯并呋喃-7-基)氧基)丙腈的制备
8.2g(50mmol)呋喃酚,26.5g(500mmol)丙烯腈,0.7g(5mmol)碳酸钾,0.37g(5mmol)叔丁醇,氮气保护。升温至回流,反应48h。停止加热后,加入0.46g(4mmol)85%磷酸淬灭反应。减压蒸馏回收丙烯腈14.27g,加入二氯甲烷溶解搅拌,抽滤后取滤液。用50mL浓度为2mol/L的氢氧化钠溶液和3mLDMSO混合溶液洗涤两次,50mL二氯甲烷再反萃一次。饱和食盐水洗两次。无水硫酸钠干燥后,减压蒸馏去除二氯甲烷,得到白色晶体3-((2,2-二甲基-2,3-二氢苯并呋喃-7-基)氧基)丙腈。收率75.1%,m.p.56~58℃。1HNMR(400MHz,DMSO)δ:1.42(s,6H,2×CH3),2.97(t,J=6.0Hz,2H,CNCH2),3.00(s,2H,CH2),4.15(s,2H,OCH2),6.71~6.84(m,3H,C6H3)。
(2)3-((2,2-二甲基-2,3-二氢苯并呋喃-7-基)氧基)丙酸的制备
4.34g(20mmol)3-((2,2-二甲基-2,3-二氢苯并呋喃-7-基)氧基)丙腈,30mL浓盐酸,回流2h。停止反应后,将混合液倒入100mL冰水中,静置,抽滤,将滤饼溶于200mL5%的碳酸氢钠溶液中,二氯甲烷洗涤3次,用5%的碳酸氢钠溶液反萃取一次,用18%的盐酸将pH值调到中性,将析出的固体抽滤,干燥,得到橘红色固体3-((2,2-二甲基-2,3-二氢苯并呋喃-7-基)氧基)丙酸,收率80.0%。
(3)2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
30mL多聚磷酸,搅拌升温至60℃,加入4.72g(20mmol)3-((2,2-二甲基-2,3-二氢苯并呋喃-7-基)氧基)丙酸,反应1.5h。停止反应后,将反应温度降至10℃以下,加入100mL冰水至反应体系中继续搅拌0.5h。用150mL乙酸乙酯萃取,再用200mL2mol/L氢氧化钠洗涤。减压蒸馏除去乙酸乙酯,柱层析[V石油醚:V乙酸乙酯=2:1]得黄绿色固体。收率36.5%,m.p.138~140℃。1HNMR(400MHz,CDCl3)δ:1.54(s,6H,2×CH3),2.82(t,J=6.4Hz,2H,COCH2),3.07(s,2H,CH2),4.60(t,J=6.4Hz,2H,OCH2),6.82(d,J=7.9Hz,1H,C6H2),7.43(d,J=7.9Hz,1H,C6H2)。
实施例2
7-(3-羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
将1.5mmol2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、1.55mmol4-羟基苯甲醛加入到100mL三口瓶中,然后加入8mL85%磷酸,磁力搅拌升温至80℃。TLC监测原料反应完全后,停止加热,待反应混合物冷却后,加入适量冰水搅拌数分钟,用适量乙酸乙酯萃取粗产物,饱和碳酸氢钠洗涤有机层,饱和食盐水洗,干燥,脱溶,乙醇重结晶得到棕黄色固体,收率63.9%,m.p.204~207℃。1HNMR(400MHz,DMSO)δ:1.45(s,6H,2×CH3),3.09(s,2H,CH2),5.37(s,2H,OCH2),6.80~6.90(m,3H,C6H4),6.97(d,J=8.0Hz,1H,C6H2),7.28~7.34(m,1H,C6H4),7.39(d,J=8.0Hz,1H,C6H2),7.65(s,1H,=CH),9.74(s,1H,OH);13CNMR(100MHz,DMSO)δ:28.06,42.96,67.60,88.88,116.75,117.12,118.84,119.21,121.49,122.00,130.34,130.98,135.23,136.10,137.11,145.60,146.44,157.41,181.53。
实施例3
7-(4-羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应12h,粗品经柱层析[V石油醚:V乙酸乙酯=2:1]得到黄色固体,收率57.1%,m.p.203~205℃。1HNMR(400MHz,DMSO)δ:1.44(s,6H,2×CH3),3.08(s,2H,CH2),5.39(s,2H,OCH2),6.89(d,J=8.0Hz,2H,C6H4),6.95(d,J=7.8Hz,1H,C6H2),7.33(d,J=8.0Hz,2H,C6H4),7.36(d,J=7.8Hz,1H,C6H2),7.66(s,1H,=CH),10.14(s,1H,OH);13CNMR(100MHz,DMSO)δ:28.07,42.93,67.79,88.79,116.03,118.68,119.12,122.15,125.15,128.02,133.03,135.76,137.35,145.39,146.39,159.19,181.41。
实施例4
7-(3,4-二羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应11h,乙醇重结晶得到黄色固体,收率44.8%,m.p.214~216℃。1HNMR(400MHz,DMSO)δ:1.44(s,6H,2×CH3),3.07(s,2H,CH2),5.38(s,2H,OCH2),6.75~6.90(m,3H,C6H3),6.94(d,J=7.8Hz,1H,C6H2),7.35(d,J=7.8Hz,1H,C6H2),7.57(s,1H,=CH),9.26(s,1H,OH),9.66(s,1H,OH)。
实施例5
7-(3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应11.5h,粗品经柱层析[V石油醚:V乙酸乙酯=8:1]得黄色固体,收率57.5%,m.p.119~121℃。1HNMR(400MHz,CDCl3)δ:1.54(s,6H,2×CH3),3.08(s,2H,CH2),3.83(s,3H,OCH3),5.39(s,2H,OCH2),6.80~6.91(m,3H,C6H2,C6H4),6.92~6.99(m,1H,C6H4),7.32~7.38(m,1H,C6H4),7.56(d,J=8.0Hz,1H,C6H2),7.83(s,1H,=CH)。
实施例6
7-(4-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应10.5h,粗品经柱层析[V石油醚:V乙酸乙酯=8:1]得淡黄色固体,收率46.6%,m.p.132~134℃。1HNMR(400MHz,CDCl3)δ;1.54(s,6H,2×CH3),3.08(s,2H,CH2),3.86(s,3H,OCH3),5.42(s,2H,OCH2),6.87(d,J=8.0Hz,1H,C6H2),6.97(d,J=8.8Hz,2H,C6H4),7.28(d,J=8.8Hz,2H,C6H4),7.56(d,J=8.0Hz,1H,C6H2),7.83(s,1H,=CH)。
实施例7
7-(3,4,5-三甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应10h,粗品经柱层析[V石油醚:V乙酸乙酯=8:1]得到棕色固体,收率46.2%,m.p.125~127℃。1HNMR(400MHz,CDCl3)δ:1.54(s,6H,2×CH3),3.09(s,2H,CH2),3.88(s,6H,2×OCH3),3.91(s,3H,OCH3),5.46(s,2H,OCH2),6.54(s,2H,C6H4),6.89(d,J=8.0Hz,1H,C6H2),7.56(d,J=8.0Hz,1H,C6H2),7.79(s,1H,=CH)。
实施例8
7-(4-羟基-3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应11h,粗品经柱层析[V石油醚:V乙酸乙酯=4:1]得黄色固体,收率55.3%,m.p.136~138℃。1HNMR(400MHz,DMSO)δ:1.54(s,6H,2×CH3),3.08(s,2H,CH2),3.92(s,3H,OCH3),5.44(s,2H,OCH2),6.83~6.89(m,3H,C6H3),6.98(d,J=8.0Hz,1H,C6H2),7.56(d,J=8.0Hz,1H,C6H2),7.80(s,1H,=CH)。
实施例9
7-(3-羟基-4-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应11h,乙醇重结晶得到棕黄色固体,收率59.6%,m.p.194~196℃。1HNMR(400MHz,DMSO)δ:1.45(s,6H,2×CH3),3.09(s,2H,CH2),3.85(s,3H,OCH3),5.40(s,2H,OCH2),6.90~6.92(m,2H,C6H32,6-H),6.96(d,J=8.0Hz,1H,C6H2),7.05(d,J=8.4Hz,1H,C6H35-H),7.37(d,J=8.0Hz,1H,C6H2),7.61(s,1H,=CH),9.36(s,1H,OH);13CNMR(100MHz,DMSO)δ:28.13,42.97,55.89,67.77,88.72,112.33,117.32,118.65,119.11,122.18,123.28,126.80,128.80,135.69,137.13,145.45,146.45,146.51,149.58,181.19。
实施例10
7-(2-羟基-3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应11h,粗品经柱层析[V石油醚:V乙酸乙酯=3:1]得到黄色固体,收率48.1%,m.p.178~180℃。1HNMR(400MHz,DMSO)δ:1.43(s,6H,2×CH3),3.08(s,2H,CH2),3.84(s,3H,OCH3),5.26(s,2H,OCH2),6.70~6.73(m,1H,C6H3),6.87(t,J=8.0Hz,1H,C6H34-H),6.93~6.97(m,1H,C6H3),7.08(d,J=8.0Hz,1H,C6H2),7.38(d,J=8.0Hz,1H,C6H2),7.84(s,1H,=CH),9.41(s,1H,OH)。
实施例11
7-(2-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应11h,乙醇重结晶得到淡黄色固体,收率57.1%,m.p.142~145℃。1HNMR(400MHz,CDCl3)δ:1.44(s,6H,2×CH3),3.10(s,2H,CH2),5.17(s,2H,OCH2),7.00(d,J=8.0Hz,1H,C6H2),7.42(d,J=8.0Hz,1H),7.43~7.48(m,1H,C6H4),7.72~7.78(m,1H,C6H4),7.85~7.90(m,1H,C6H4),7.93(s,1H,=CH),8.25~8.31(m,1H,C6H4)。
实施例12
7-(3-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
1.5mmol2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、5mL乙醇和适量5%NaOH溶液,室温搅拌,缓慢加入1.55mmol3-硝基苯甲醛,TLC跟踪反应,视反应情况补加适量5%NaOH水溶液。TLC监测反应完全后,向反应液中加入适量冰水搅拌15分钟,析出黄色沉淀,抽滤,冰水洗涤滤饼,冰乙醇淋洗滤饼,乙醇重结晶得到黄色固体,收率68.0%,m.p.231~234℃。1HNMR(400MHz,DMSO)δ:1.44(s,6H,2×CH3),3.09(s,2H,CH2),5.41(s,2H,OCH2),6.99(d,J=8.0Hz,1H,C6H2),7.40(d,J=8.0Hz,1H,C6H2),7.79~7.89(m,3H,C6H4),8.26~8.34(m,2H,C6H4,=CH)。
实施例13
7-(4-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应10h,乙酸乙酯重结晶得到黄色固体,收率61.9%,m.p.238~241℃。1HNMR(400MHz,DMSO)δ:1.44(s,6H,2×CH3),3.09(s,2H,CH2),5.39(s,2H,OCH2),6.99(d,J=8.0Hz,1H,C6H2),7.40(d,J=8.0Hz,1H,C6H2),7.73(d,J=8.0Hz,2H,C6H42,6-H),7.81(s,1H,=CH),8.32(d,J=8.0Hz,2H,C6H43,5-H)。
实施例14
7-(2-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
1.0mmol7-(3-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮,10mL二氯甲烷和10ml乙酸搅拌溶解,加入适量铁粉和1mL水,室温搅拌反应6h。过滤,二氯甲烷洗滤饼,3×20mL水洗滤液,2×20mL饱和NaHCO3洗至无絮状物,干燥,脱溶,乙醇重结晶得棕黄色固体,收率82.2%,m.p.182~184℃。1HNMR(400MHz,DMSO)δ:1.43(s,6H,2×CH3),3.07(s,2H,CH2),5.26(s,2H,OCH2),5.49(s,2H,NH2),6.59(t,J=7.2Hz,1H,C6H4),6.70~6.89(m,2H,C6H4),6.95(d,J=7.8Hz,1H,C6H2),7.13(t,J=7.5Hz,1H,C6H4),7.39(d,J=7.8Hz,1H,C6H2),7.68(s,1H,=CH)。
实施例15
7-(3-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例14方法,乙醇重结晶得黄色固体,收率74.6%,m.p.152~155℃。1HNMR(400MHz,DMSO)δ:1.44(s,6H,2×CH3),3.08(s,2H,CH2),5.29(s,1H,OCH2),5.36(s,2H,NH2),6.69~6.52(m,3H,C6H4),6.96(d,J=7.8Hz,1H,C6H2),7.09~7.19(m,1H,C6H4),7.37(d,J=7.8Hz,1H,C6H2),7.58(s,1H,=CH)。
实施例16
7-(4-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应11.5h,乙醇重结晶得到橘黄色固体,收率44.5%,m.p.146~149℃。1HNMR(400MHz,DMSO)δ:1.45(s,6H,2×CH3),3.08(s,2H,CH2),5.40(s,2H,OCH2),5.95(s,2H,NH2),6.65(d,J=8.5Hz,2H,C6H4),6.93(d,J=8.0Hz,1H,C6H2),7.19(d,J=8.5Hz,2H,C6H4),7.34(d,J=8.0Hz,1H,C6H2),7.59(s,1H,=CH);13CNMR(100MHz,DMSO)δ:28.17,42.99,68.16,88.53,113.81,118.37,118.96,121.36,122.53,125.14,133.30,135.09,138.10,145.26,146.42,151.29,180.85。
实施例17
7-(4-羧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应10.5h,乙醇重结晶得黄色固体,收率55.2%,m.p.274~277℃。1HNMR(400MHz,DMSO)δ:1.44(s,6H,2×CH3),3.09(s,2H,CH2),5.39(s,2H,OCH2),6.98(d,J=8.0Hz,1H,C6H2),7.39(d,J=8.0Hz,1H,C6H2),7.57(d,J=8.0Hz,2H,C6H42,6-H),7.77(s,1H,=CH),8.03(d,J=8.0Hz,2H,C6H43,5-H)。
实施例18
7-(4-二甲氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮的制备
按例2方法,反应12h,乙醇重结晶得橘黄色固体F28,收率57.8%,m.p.202~204℃。1HNMR(400MHz,DMSO)δ:1.44(s,6H,2×CH3),3.01(s,6H,2×CH3,C6H4),3.07(s,2H,CH2),5.42(s,2H,OCH2),6.79(d,J=8.4Hz,2H,C6H43,5-H),6.93(d,J=8.0Hz,1H,C6H2),7.34(m,3H,C6H2,C6H42,6-H),7.65(s,1H,=CH)。
实施例19
7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物的抗流感病毒神经氨酸酶活性
1.实验原理
化合物MUNANA是神经氨酸酶的特异性底物,在神经氨酸酶作用下产生的代谢产物在360nm照射激发下,可以产生450nm荧光,荧光强度的变化可以灵敏地反应神经氨酸酶活性。酶都来自A/PR/8/34(H1N1)病毒毒株。
2.实验方法
在酶反应体系中,一定浓度样品与流感病毒神经氨酸酶NA悬浮于反应缓冲液中(pH6.5),加入荧光底物MUNANA启动反应体系,37℃孵育40分钟后,加反应终止液终止反应。在激发波长360nm和发射波长为450nm的参数条件下,测定荧光强度值。反应体系的荧光强度可以反映酶的活性。根据荧光强度的减少量可以计算化合物对NA活性的抑制率。
3.检测样品:实施例化合物
4.活性结果
优选化合物在反应系统中检测浓度40.0μg/mL时对神经氨酸酶的抑制率和IC50列入下表:
表17,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物(40.0μg/mL)对神经氨酸酶的抑制率和IC50(μg/mL)
由表中数据可知7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮对神经氨酸酶具有较好的抑制活性,可应用于制备神经氨酸酶抑制剂。
Claims (5)
1.一类化学结构式Ⅰ所示的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物及其药学上可接受的盐:
其中R选自:氢、氘、C1~C2烷基、C3~C5直链烷基或C3~C5支链烷基;X1、X5选自:氢、C1~C2烷基、C3~C4直链或支链烷基、羟基、甲氧基、乙氧基;X2、X4选自:氢、C1~C2烷基、C3~C4直链或支链烷基、硝基、羟基、甲氧基、乙氧基或氨基;X3选自:氢、C1~C2烷基、C3~C4直链或支链烷基,羟基、甲氧基、乙氧基、二甲氨基或羧基。
2.权利要求1所述的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物及其药学上可接受的盐,其特征在于,所述的化合物选自:
7-(3-羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(4-羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(3,4-二羟基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(4-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(3,4,5-三甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(4-羟基-3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(3-羟基-4-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(2-羟基-3-甲氧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(2-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(3-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(4-硝基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(2-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(3-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(4-氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮、
7-(4-羧基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮或
7-(4-二甲氨基亚苄基)-2,2-二甲基-7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮。
3.权利要求1所述的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物的制备方法,其特征在于它的制备反应如下:
式中,R、X1~X5如权利要求1所述。
4.权利要求1或2所述的7,8-二氢-2H-呋喃并[3,2-h]色满-6(3H)-酮衍生物在制备流感病毒神经氨酸酶抑制剂中的应用。
5.一种药物组合物,包括权利要求1~2至少一种化合物和制药学上可用的载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610098585.4A CN105541859B (zh) | 2016-02-23 | 2016-02-23 | 二氢呋喃并色满酮衍生物及其制备方法与医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610098585.4A CN105541859B (zh) | 2016-02-23 | 2016-02-23 | 二氢呋喃并色满酮衍生物及其制备方法与医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105541859A true CN105541859A (zh) | 2016-05-04 |
CN105541859B CN105541859B (zh) | 2017-12-29 |
Family
ID=55821464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610098585.4A Expired - Fee Related CN105541859B (zh) | 2016-02-23 | 2016-02-23 | 二氢呋喃并色满酮衍生物及其制备方法与医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105541859B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107098916A (zh) * | 2017-06-22 | 2017-08-29 | 湖南大学 | 7‑(吡啶亚甲基)二氢呋喃并色满酮及其制备方法与应用 |
CN107334760A (zh) * | 2017-06-22 | 2017-11-10 | 湖南大学 | 7‑亚苄基二氢呋喃并色满酮在制备抗癌药中的应用 |
CN111925377A (zh) * | 2020-08-31 | 2020-11-13 | 上海应用技术大学 | 对位取代的二氢呋喃香豆素类神经氨酸酶抑制剂及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103070858A (zh) * | 2012-12-27 | 2013-05-01 | 中山大学 | 苯骈α-吡喃酮类化合物作为抗γ型人类疱疹病毒药物的应用 |
WO2015081199A1 (en) * | 2013-11-27 | 2015-06-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating herpesvirus infection |
CN105111221A (zh) * | 2015-09-28 | 2015-12-02 | 湖南大学 | 呋喃并色满-6-肟衍生物及其制备方法与应用 |
-
2016
- 2016-02-23 CN CN201610098585.4A patent/CN105541859B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103070858A (zh) * | 2012-12-27 | 2013-05-01 | 中山大学 | 苯骈α-吡喃酮类化合物作为抗γ型人类疱疹病毒药物的应用 |
WO2015081199A1 (en) * | 2013-11-27 | 2015-06-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating herpesvirus infection |
CN105111221A (zh) * | 2015-09-28 | 2015-12-02 | 湖南大学 | 呋喃并色满-6-肟衍生物及其制备方法与应用 |
Non-Patent Citations (2)
Title |
---|
HYUNG JAE JEONG,等: "Homoisoflavonoids from Caesalpinia sappan Displaying Viral Neuraminidases Inhibition", 《BIOL. PHARM. BULL.》 * |
VIDAVALUR SIDDAIAH,等: "Synthesis, structural revision, and antioxidant activities of antimutagenic homoisoflavonoids from Hoffmanosseggia intricata", 《BIOORG. MED. CHEM. LETT.》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107098916A (zh) * | 2017-06-22 | 2017-08-29 | 湖南大学 | 7‑(吡啶亚甲基)二氢呋喃并色满酮及其制备方法与应用 |
CN107334760A (zh) * | 2017-06-22 | 2017-11-10 | 湖南大学 | 7‑亚苄基二氢呋喃并色满酮在制备抗癌药中的应用 |
CN107098916B (zh) * | 2017-06-22 | 2019-04-12 | 湖南大学 | 7-(吡啶亚甲基)二氢呋喃并色满酮及其制备方法与应用 |
CN111925377A (zh) * | 2020-08-31 | 2020-11-13 | 上海应用技术大学 | 对位取代的二氢呋喃香豆素类神经氨酸酶抑制剂及其制备方法和应用 |
CN111925377B (zh) * | 2020-08-31 | 2022-05-31 | 上海应用技术大学 | 对位取代的二氢呋喃香豆素类神经氨酸酶抑制剂及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105541859B (zh) | 2017-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104024213A (zh) | 合成的表没食子儿茶素没食子酸酯(egcg)类似物 | |
CN105541859A (zh) | 二氢呋喃并色满酮衍生物及其制备方法与医药用途 | |
CN102311449A (zh) | 棉酚衍生物在制备抗肿瘤药物中的应用 | |
CN102702155B (zh) | 基于体内代谢机制的灯盏乙素苷元甲基化产物及其制备方法和其应用 | |
CN105693665B (zh) | 含苯并呋喃环的芳甲酰腙衍生物及其制备方法与医药用途 | |
CN101613334B (zh) | 黄酮类衍生物及其医药用途 | |
CN105622558A (zh) | 含苯并呋喃环的酰腙衍生物及其制备方法与应用 | |
CN102992988B (zh) | 一种取代间苯三酚衍生物及其应用 | |
CN108503604A (zh) | (4-烷基-5-酰基-2-噻唑)腙衍生物及其医药用途 | |
CN104910119A (zh) | 一类香豆素取代黄酮类衍生物及其制备方法和应用 | |
JP6404220B2 (ja) | テアニン誘導体とカルボン酸クマリン誘導体との縮合生成物、その中間体、調製方法、及びその使用 | |
CN110229081B (zh) | 2,4-二硝基苯腙衍生物及其制备方法与应用 | |
CN105669589A (zh) | 2-(5-酰基噻唑-2-亚氨基)-4-噻唑啉酮及其制备方法与应用 | |
CN102731459A (zh) | 灯盏乙素苷元Mannich衍生物及其制备方法和应用 | |
CN102382076B (zh) | 芳酮和芳酰胺类化合物及其制法和药物用途 | |
CN101062925B (zh) | 紫杉醇衍生物、其制备方法和其药物组合物与用途 | |
CN104177377A (zh) | 3位双胺β-咔啉碱类化合物、其制法和其药物组合物与用途 | |
CN105541591A (zh) | 1-(4-羟基-3-芳基苯基)-2-丙酮及其制备方法与应用 | |
CN102382036A (zh) | 苯氧乙酸类化合物及其制法和药物用途 | |
CN107334760B (zh) | 7-亚苄基二氢呋喃并色满酮在制备抗癌药中的应用 | |
CN111100074B (zh) | 哒嗪腙衍生物及其制备方法与应用 | |
CN108689961B (zh) | 2-(5-硝基噻唑-2-基)亚氨基-4-噻唑啉酮衍生物及其制备方法与应用 | |
CN110903221B (zh) | 碳酰二腙衍生物及其制备方法与应用 | |
CN111909082B (zh) | 吡啶腙衍生物及其制备方法与应用 | |
CN109053606B (zh) | 4-(4-羟基苯基亚甲氨基)-1,2,4-三唑-5-硫酮及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171229 |
|
CF01 | Termination of patent right due to non-payment of annual fee |